Imagine if a common healthcare-associated infection became impossible to treat. The nightmare scenario public health officials are contemplating is that an emerging strain of multidrug-resistant Candida auris will displace treatable strains of Candida, which are already a leading cause of bloodstream infections.
In a recently published report on antibiotic threats in the United States, the Centers for Disease Control and Prevention classified pathogens as urgent, serious, concerning, or put them on a “watch list.”
In a large, randomized, double-blind, multicenter clinical trial, researchers found that isavuconazole did not meet the primary endpoint of noninferiority compared to caspofungin for candidemia and invasive candidiasis.
A retrospective cohort study found that endogenous fungal endophthalmitis is associated with intravenous drug use and frequently results in poor visual outcomes despite appropriate surgical and antifungal therapy.
Two hundred sixty non-neutropenic ICU patients with clinical evidence of sepsis receiving broad-spectrum antibiotics and known to be colonized by Candida species were randomized to micafungin for 14 days vs. placebo. Empirical micafungin therapy did not increase invasive fungal infection-free survival at 28 days.